What year were specialty drugs designated?
Specialty drugs in the United States
In September 2015, Martin Shkreli was criticized by several health organizations[96] for obtaining manufacturing licenses on old, out-of-patent,[97] life-saving medicines including pyrimethamine (brand name Daraprim), which is used to treat patients with toxoplasmosis, malaria, some cancers, and AIDS,[98] and then increasing the price of the drug in the US from $13.50 to $750 per pill, a 5,455% increase.[99][100] In an interview with Bloomberg News, Shkreli claimed that despite the price increase, patient co-pays would be lower, that many patients would get the drug at no cost, that the company has expanded its free drug program, and that it sells half of the drugs for one dollar.[101][102]